Development and validation of a LC-FL method for the simultaneous determination of doxorubicin and celecoxib in nanoparticulate fixed dose combination (NanoFDC)


Kozlu S., ŞAHİN A. E. , ÇALIŞ S., ÇAPAN Y.

PHARMAZIE, vol.72, no.10, pp.568-570, 2017 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 72 Issue: 10
  • Publication Date: 2017
  • Doi Number: 10.1691/ph.2017.7077
  • Journal Name: PHARMAZIE
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.568-570

Abstract

An isocratic reversed phase HPLC method for the simultaneous determination of doxorubicine (DOX) and celecoxib (CXB) out of a nanoparticulate fixed dose combination (NanoFDC) was developed and validated. Linearity of the results was demonstrated from 1-11 mu g/mL for both components. Lower limits of detection were determined as 7 ng/mL for DOX and 13 ng/mL for CXB. Total run time was approximately 15 min.